1. Wexler R, Feldman D. Hypertension: which drugs to choose for patients with cardiovascular disease. J Fam Pract 2006;55:291-298.
2. Cheung BMY, Ong KL, Man YB, Lam KSL, Lau CP. Prevalence, Awareness, Treatment, and Control of Hypertension: United States National Health and Nutrition Examination Survey 2001–2002. J Clin Hypertens 2006;8:93-98.
3. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2004;42:1206-1252.
4. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913.
5. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001;103:1245-1249.
6. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcomes trials. Lancet 2000;355:865-872.
7. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005;45:907-913.
8. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006;May 31.
9. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-79.
10. Reeves MJ, Rafferty AP. Healthy lifestyle characteristics among adults in the United States, 2000. Arch Intern Med 2005;165:854-857.
11. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006;47:345-351.
12. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427.
13. Weir MR. Providing end-organ protection with renin-angiotensin system inhibition: the evidence so far. J Clin Hypertens 2006;8:99-105.
14. Weir MR. Angiotensin II receptor blockers: the importance of dose in cardiovascular and renal risk reduction. J Clin Hypertens 2004;6:315-323.
15. Sica DA. Pharmacotherapy review: angiotensin receptor antagonists. J Clin Hypertens 2005;7:681-684.
16. US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statistics, 2002.
17. Hyman DJ, Pavlik VN. Self-reported hypertension practices among primary care physicians: Blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 2000;160:2281-2286.
